Drug Safety Analysis via Comparator Event Filtering
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The current drug approval process is insufficient in identifying safety concerns early enough, as safety issues often emerge only after widespread use by a large patient population, leading to delayed safety recalls.
Innovation Solution
A method and system utilizing a healthcare claims database to identify and compare medical events of new drugs with those of comparator drugs, computing probability values for common occurrences, and filtering data by patient demographics and conditions to quantify potential safety concerns.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If the drug approval process is accelerated to shorten the approval period, then the productivity of drug approval is improved, but the reliability of safety identification deteriorates because safety issues do not become apparent until after widespread usage
Solution Approach 1:
The system performs preliminary safety analysis by comparing new drug medical events with comparator drugs before widespread usage occurs. This early comparison identifies potential safety concerns during the initial market entry phase rather than waiting for long-term accumulation of usage data, thus maintaining fast approval while improving safety identification reliability.
2Measurement precision
If a large patient population is required to identify safety issues, then the measurement precision of safety concerns is improved, but the loss of time increases because safety recalls are delayed until after widespread usage
Solution Approach 1:
The system uses a partial population approach by selecting a representative sample of new drug patients and comparing them with comparator drug patients. This partial analysis provides sufficient statistical power to identify safety signals early without requiring the excessive time needed for complete widespread usage accumulation, thus reducing time loss while maintaining adequate measurement precision.
Solution Approach 2:
The system rushes through the safety identification process by implementing continuous monitoring and early comparison methods that skip the traditional waiting period for long-term usage data. This allows safety concerns to be identified and acted upon much faster than conventional approaches.
3Quantity of substance
If comprehensive medical event data is collected from all patients, then the quantity of information for safety analysis is improved, but the complexity of data processing increases
Solution Approach 1:
The system extracts only the relevant medical events and comparator drug data needed for safety comparison, rather than processing all available patient data. This selective extraction reduces data processing complexity while maintaining sufficient information volume to identify safety concerns effectively.
Solution Approach 2:
The data processing system is segmented into modular components that handle specific tasks: identifying new drug patients, extracting medical events, selecting comparator drugs, and comparing outcomes. This segmentation reduces overall system complexity by breaking down the comprehensive data analysis into manageable, specialized processing steps.
Data Source
AI summary
A system and method for identifying safety concerns regarding a drug identify a first group of patients that have received the drug from a database of healthcare claims and extract one or more medical events that the first group of patients have experienced from the database. The system and method also identify a second group of patients that have received a comparator drug in the database and extract one or more medical events that the second group of patients have experienced. The medical events of the first group are compared to the medical events of the second group to determine at least one common occurrence therebetween. The common occurrence(s) is then filtered based upon one or more user defined outcomes, each including at least one diagnosis, procedure or therapeutic classification; non-medical criteria; and/or patient laboratory test data.